A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence

Journal of Clinical Psychopharmacology

Volumn 28, Issue 1, 2008, Pages 5-12

  Anton, Raymond F ^a   Kranzler, Henry ^b   Breder, Christopher ^c   Marcus, Ronald N ^c   Carson, William H ^d   Han, Jian ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIPYRETIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CARBOHYDRATE; PLACEBO; SEDATIVE AGENT; TRANSFERRIN;

ADULT; AGED; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DISTURBANCE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

ADULT; AGED; ALCOHOLISM; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; TEMPERANCE; TREATMENT OUTCOME;

EID: 38349116198     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e3181602fd4     Document Type: Article

References (31)

1. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci. 2000;909:170-185.
2. Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol. 2005;526:199-206.
3. Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol. 2005;526:163-171.
4. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18:10663-10671.
5. Katner SN, Weiss F. Ethanol-associated olfactory stimuli reinstate ethanol-seeking behavior after extinction and modify extracellular dopamine levels in the nucleus accumbens. Alcohol Clin Exp Res. 1999;23:1751-1760.
6. Middaugh LD, Szumlinski KK, Van Patten Y, et al. Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone. Alcohol Clin Exp Res. 2003;27:1892-1900.
7. Middaugh LD, Bandy AL. Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology (Berl). 2000;151:321-327.
8. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005;8:1442-1444.
9. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
10. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
11. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26: 649-666.
12. Ingman K, Kupila J, Hyytia P, et al. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol. 2006;41:391-398.
13. Warsi M, Sattar SP, Bhatia SC, et al. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005;50:244.
14. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25:363-366.
15. Babor TF, Longabaugh R, Zweben A, et al. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol Suppl. 1994;12:101-111.
16. Anton RF, Randall CL. Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl. 2005;15:104-109.
17. Sullivan J, Sykora K, Schneiderman J. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357.
18. Kadden R, Carroll K, Donovan D, et al. Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1994. Test manual, NIAAA Project MATCH Monograph Series, DHHS Pub. No. 94-3742.
19. Miller W, Zweben A, DiClemente C, et al. Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1994. Test manual, NIAAA Project MATCH Monograph Series, Vol. 2. DHHS Pub. No. 94-3723.
20. Nowinski J, Baker S, Carroll K. Twelve Step Facilitation Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1994. Test manual, NIAAA Project MATCH Monograph Series. DHHS Pub. No. 94-3722.
21. Project MRG. Matching alcohol treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58:7-29.
22. Sobell L, Sobell M. Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption. Totowa, NJ: Humana Press; 1992.
23. Miller WR, Del Boca FK. Measurement of drinking behavior using the Form 90 family of instruments. J Stud Alcohol Suppl. 1994;12:112-118.
24. Roberts J, Anton R, Latham P, et al. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999;23:1484-1491.
25. Miller W, Tonigan J, Longabaugh R. The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Washington, DC: US Government Printing Office; 1995. Test manual, NIAAA Project MATCH Monograph Series. NIH Pub. No. 95-3911.
26. Rush A, Trivedi M, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR16): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;56:573-583.
27. Skinner H, Allen B. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91:199-209.
28. Anton RF, Dominick C, Bigelow M, et al. Comparison of Bio-Rad %CDT TIA and CDTect as laboratory markers of heavy alcohol use and their relationships with gamma-glutamyltransferase. Clin Chem. 2001;47:1769-1775.
29. Kranzler H, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
30. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40:383-393.
31. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.